Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 89
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Times cited: 29
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Times cited: 66